Skip to main content

Table 3 Appearance of liver dysfunction and diarrhea within 180 days after treatment

From: Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia

Number of patients Standard dose (n = 10) Dose escalation (n = 15) P value
Patient with liver dysfunction (> grade 1) (%) 5 (50.0%) 4 (26.7%) 0.234
Maximum grade (grade 2/3/4) 4/1/0 1/2/1  
Day of the appearance of liver dysfunction (> grade 1), median (range) 28 (19–57) 53.5 (35–112)  
Cumulative dose until the appearance of liver dysfunction over grade 2, mg, median (range) 8500 (6500–20,500) 11,300 (5500–36,300) 0.806
Dose at the appearance of liver dysfunction over grade 2, median (range) 400 (400–500) 350 (200–500) 0.241
Discontinuation of bosutinib due to liver dysfunction (%) 0 (0%) 1 (6.6%)  
Patient with diarrhea (all grade) (%) 10 (100%) 11 (73.3%) 0.075
Maximum grade (grade 0/1/2/3/4) 0/4/3/3/0 4/6/2/3/0  
Day of the first appearance of diarrhea, median (range) 1 (1–5) 19 (1–148) < 0.0001
Dose at the first appearance of diarrhea (100/200/300/400/500 mg) 0/0/0/0/10 4/3/1/3/0  
Cumulative days of diarrhea, median (range) 20.5 (3–47) 6 (1–27) 0.104
Discontinuation of bosutinib due to diarrhea (%) 0 (0%) 0 (0%)